Core Viewpoint - 康龙化成 (300759) announced a placement of approximately 58.44 million new H-shares, leading to a decline of over 7% in its stock price, indicating market reaction to the dilution of shares and the pricing of the placement [1] Group 1: Share Placement Details - The share placement represents about 3.19% of the company's expanded total issued shares and approximately 16.57% of the total issued H-shares [1] - The placement price is set at HKD 22.82 per share, which reflects an 8.5% discount compared to the closing price on January 14 [1] - The expected total gross proceeds from the placement are approximately HKD 1.334 billion, with net proceeds estimated at HKD 1.319 billion [1] Group 2: Use of Proceeds - Approximately 70% of the proceeds will be allocated for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] - About 10% of the funds will be used to repay bank loans and other borrowings to optimize the capital structure [1] - The remaining 20% will be utilized to supplement working capital and for other general purposes [1]

Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to raise approximately HKD 1,333.6 million [1][2] Group 1 - The placement shares represent approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the net proceeds from the placement are expected to be around HKD 1,318.7 million, with a net price per share of approximately HKD 22.56 [2] - The company plans to allocate about 70% of the net proceeds for project construction to enhance laboratory service facilities and production capacity [2] Group 2 - Approximately 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the company's capital structure [2] - About 20% of the funds will be allocated to supplement working capital and other general corporate purposes [2] - The board believes that this issuance will strengthen the company's financial position, capture industry opportunities, and support capacity investment and business expansion [2]

Core Viewpoint - 康龙化成 has signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong to issue 58,440,762 new H-shares at a price of HKD 22.82 per share, aiming to strengthen its capital structure and support business expansion [1][2] Group 1: Placement Details - The number of placement shares represents approximately 19.86% of the existing issued H-shares and 3.30% of the total issued shares as of the announcement date [1] - If fully subscribed, the total proceeds from the placement are expected to be approximately HKD 1,333.6 million, with a net amount of about HKD 1,318.7 million [2] - The net price per placement share is approximately HKD 22.56 [2] Group 2: Use of Proceeds - Approximately 70% of the net proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [2] - About 10% will be allocated to repay bank loans and other borrowings to optimize the company's capital structure [2] - Approximately 20% will be used to supplement working capital and for other general corporate purposes [2] Group 3: Strategic Implications - The board believes that the company is a leading integrated pharmaceutical R&D and manufacturing service platform, committed to strengthening service capabilities and accelerating global drug innovation [2] - The issuance is expected to enhance the company's financial strength, capture industry opportunities, and support capacity investment and business expansion [2] - The placement will introduce high-quality international institutional investors, expand the shareholder base, and significantly enhance the liquidity of H-shares [2]

Core Viewpoint - 康龙化成 announced a placement of approximately 58 million new H-shares at a price of HKD 22.82 per share, representing an 8.5% discount to the closing price on Wednesday [1] Group 1: Share Placement Details - The placement price is set at HKD 22.82 per share [1] - The new shares represent 3.19% of the total issued share capital post-placement [1] - The company aims to raise approximately HKD 1.33 billion through this placement [1] Group 2: Use of Proceeds - The funds raised will be utilized for project construction, working capital, repayment of bank loans, and other borrowings [1] Group 3: Financial Coordination - Goldman Sachs and HSBC are acting as joint global coordinators for the share placement [1]

2026年1月14日(交易时段后)，公司与高盛(亚洲)有限责任公司及香港上海汇丰银行有限公司签署了配售 协议。根据配售协议，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公 司代理，并尽力促使若干承配人按照配售协议所载条款及条件，按每股配售股份22.82港元认购公司根 据一般发行授权拟发行的5844.0762万股新H股。 康龙化成（300759）(300759.SZ)公告，公司拟根据2024年年度股东大会审议通过的《关于股东大会给 予董事会增发公司H股股份一般性授权的议案》项下股东大会对董事会增发H股股份的授权，新增发行 境外上市外资股(H股)。 ...

Group 1 - The company, Kanglong Chemical (300759.SZ), plans to issue new H-shares based on the authorization granted by the shareholders' meeting for the board to increase the issuance of H-shares [1] - On January 14, 2026, the company signed a placement agreement with Goldman Sachs (Asia) LLC and HSBC Hong Kong, appointing them as placement agents [1] - The company intends to issue 58,440,762 new H-shares at a subscription price of HKD 22.82 per share according to the terms of the placement agreement [1]

Group 1 - Company announced that its third board meeting was held on January 14, 2026, via telecommunication, where it reviewed the proposal for the general authorization to issue new H-shares [1] Group 2 - The introduction of a "budget version" of the Tesla Model 3 is anticipated in the Chinese market, with a range of 480 kilometers [1] - Significant adjustments are occurring in the U.S. market regarding autonomous driving [1]

证券代码：300759 证券简称：康龙化成 公告编号：2026-005 康龙化成（北京）新药技术股份有限公司 关于根据一般发行授权配售新 H 股的公告 （一）日期 2026 年 1 月 14 日（交易时间后）。 （二）订约方 发行人：康龙化成（北京）新药技术股份有限公司。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"本公司"或"公司"） 是一家领先的全流程一体化医药研发生产服务平台，业务遍及全球，致力于进一 步巩固服务能力，加速全球药物创新。为进一步加强公司的资金实力，把握行业 机遇，助力产能投入与业务拓展，经公司第三届董事会第十八次会议审议通过， 公司拟根据 2024 年年度股东大会审议通过的《关于股东大会给予董事会增发公 司 H 股股份一般性授权的议案》项下股东大会对董事会增发 H 股股份的授权（以 下简称"一般发行授权"），新增发行境外上市外资股（H 股）（以下简称"本次 发行"）。 一、本次发行概述 2026 年 1 月 14 日（交易时段后），本公司与高盛（亚洲）有限责任公司及 香港上海汇丰银行有限 ...

证券代码：300759 证券简称：康龙化成 公告编号：2026-004 康龙化成（北京）新药技术股份有限公司 第三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）第三届董事 会第十八次会议通知及材料于 2026 年 1 月 14 日以邮件形式向全体董事发出，全 体董事一致同意豁免本次董事会的通知期限，本次会议于 2026 年 1 月 14 日以通 讯方式召开。会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长 Boliang Lou 博士主持，公司部分高级管理人员列席了本次会议。本次会议的召 集和召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等有关法 律、行政法规、部门规章、规范性文件和《康龙化成（北京）新药技术股份有限 公司章程》（以下简称"《公司章程》"）的规定。 公司拟根据 2024 年年度股东大会审议通过的《关于股东大会给予董事会增 发公司 H 股股份一般性授权的议案》项下股东大会对董事会增发 H 股股份的授 权（以下简称 ...

Core Viewpoint - 康龙化成 plans to raise approximately HKD 13.3 billion through the placement of new H-shares, with a focus on enhancing its laboratory and production capabilities, optimizing its capital structure, and supplementing working capital [1] Group 1: Financing Details - 康龙化成 announced the issuance of 58,440,762 new H-shares at a price of HKD 22.82, representing an 8.5% discount to the previous closing price of HKD 24.94 and a 1.6% discount to the average closing price of HKD 23.20 over the past five trading days [1] - The new shares represent approximately 3.3% of the existing issued share capital and will account for about 3.2% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 9.3 billion of the proceeds will be allocated for project construction to enhance laboratory and production capacity [1] - Around HKD 1.3 billion will be used to repay loans to optimize the capital structure [1] - Approximately HKD 2.6 billion will be designated for working capital and general corporate purposes [1] Group 3: Transaction Timeline - The issuance is based on a general authorization granted by the shareholders and is expected to be completed by January 22, 2026 [1]